QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

IDYA

QT59IDEAYA Biosciences, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
31.23
-0.03-0.10%
OverviewShort InterestFilings
IDYAQT59IDEAYA Biosciences, Inc.·NASDAQ
OverviewShort InterestFilings
31.23-0.10%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.89
Insider Own19.27%
Shs Outstand95.08M
Perf Week8.29%
Market Cap2.96BForward P/E-EPS next Y-3.70Insider Trans0.05%Shs Float-Perf Month10.28%
Enterprise Value2.83BPEG-EPS next Q-1.07Inst Own-Short Float-Perf Quarter-4.20%
Income-149351237.00P/S13.13EPS this Y-128.68%Inst Trans-Short Ratio-Perf Half Y-7.63%
Sales225.27MP/B2.96EPS next Y14.41%ROA-13.59%Short Interest-Perf YTD-9.66%
Book/sh9.85P/C-EPS next 5Y-ROE-13.96%52W High39.28 -20.49%Perf Year42.47%
Cash/sh7.06P/FCF-EPS past 3/5Y-ROIC-19.00%52W Low20.50 52.34%Perf 3Y-
Dividend Est.-EV/EBITDA-20.88Sales past 3/5Y62.54% 61.39%Gross Margin29.70%Volatility2.88% 3.57%Perf 5Y-
Dividend TTM-EV/Sales12.56EPS Y/Y TTM52.38%Oper. Margin-81.44%ATR (14)1.53Perf 10Y-
Dividend Ex-Date-Quick Ratio10.74Sales Y/Y TTM242.86%Profit Margin-62.17%RSI (14)58.35Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.74EPS Q/Q-35.37%SMA206.39%Beta1.24Target Price58.67
Payout0.00%Debt/Eq0.03Sales Q/Q-SMA505.07%Rel Volume1.52Prev Close31.26
Employees131LT Debt/Eq0.03EarningsAug 04SMA2000.04%Avg Volume1.33MPrice31.23
IPO DateMay 23, 2019Option/ShortYes / YesEPS/Sales Surpr.-3.74% 40.00%Net Debt/EBITDA0.95Volume2,018,517Change-0.10%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-14-26ReiteratedWedbushOutperform$52 → $58
Apr-14-26ReiteratedRBC CapitalOutperform$45 → $53
Apr-13-26ReiteratedTruist Financial$60 → $65
Feb-18-26ReiteratedWedbushOutperform$52
Jan-21-26ReiteratedRBC CapitalOutperform$41 → $45
Jan-06-26ReiteratedTruist Financial$59 → $60
Nov-24-25InitiatedTruistBuy$59
Oct-21-25ReiteratedNew Street$27 → $30
Oct-21-25ReiteratedRBC CapitalOutperform$38 → $41
Sep-17-25InitiatedGuggenheimBuy$32 → $50
Latest News
Jun-15-26
Jun-15-2606:05AM
Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Pancreatic And Lung CancersBenzinga
Jun-12-26
Jun-12-2610:10AM
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price TargetBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue242197
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A454
Gross Profit202143
Selling, General and Administrative Excl. Other246335
Research and Development130315295
Other Operating Expense0-50
Operating Income-135-159-327
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-22-46-52
Net Income Before Taxes-113-114-274
Income Taxes
000
Consolidated Net Income-113-114-274
Net Income From Continuing Operations-113-114-274
Net Income-113-114-274
EPS (Recurring)-1.89-1.28-3.36
EPS (Basic, Before Extraordinaries)-1.89-1.28-3.36
EPS (Diluted)-1.89-1.28-3.36
EBITDA-109-109-271
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio84.5813.89—
Gross Margin83.3397.7242.86
Operating Margin-562.50-72.60-4,671.43
Net Margin-470.83-52.05-3,914.29
Shares Outstanding658882
Market Capitalization2,0303,042—
Operating Lease Expense
———
Insider Trading Volume
$32.76$30.52$28.29$26.05$23.81● Close Price0.00M0.41M0.82M1.24M1.65MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Stein JeffreyDirectorMar 02 '26Buy32.9650,0001,647,89054,281Mar 02 12:00 AM
Hata Yujiro SPresident and CEOFeb 18 '25Option Exercise19.5225,616500,024690,695Feb 19 12:00 AM
Throne JasonChief Legal OfficerJun 27 '24Option Exercise7.77106,968831,17463,484Jun 27 12:00 AM
WHITE MICHAEL ANTHONYChief Scientific OfficerMay 29 '24Option Exercise12.8657,000733,02064,000May 31 12:00 AM
WHITE MICHAEL ANTHONYChief Scientific OfficerMay 29 '24Sale36.2428,5001,032,8850May 31 12:00 AM
Hata Yujiro SPresident and CEOMay 16 '24Sale41.8134,4331,439,755677,887May 16 12:00 AM
Hata Yujiro SPresident and CEOMay 16 '24Option Exercise4.3168,866296,812712,320May 16 12:00 AM
Hata Yujiro SPresident and CEOMay 15 '24Option Exercise4.31167,712722,838761,743May 16 12:00 AM
Hata Yujiro SPresident and CEOMay 15 '24Sale42.9083,8563,597,756677,887May 16 12:00 AM
Hata Yujiro SPresident and CEOMay 14 '24Sale41.6156,7112,359,781677,887May 16 12:00 AM
Hata Yujiro SPresident and CEOMay 14 '24Option Exercise4.31113,422488,848734,598May 16 12:00 AM
Ruiz Briseno AndresSee RemarksFeb 09 '24Sale46.022,00092,04524,531Feb 13 12:00 AM
Hata Yujiro SPresident and CEOFeb 09 '24Option Exercise4.3147,114203,062701,444Feb 12 12:00 AM
Hata Yujiro SPresident and CEOFeb 09 '24Sale45.5423,5571,072,715677,887Feb 12 12:00 AM
Hata Yujiro SPresident and CEOFeb 08 '24Sale45.1575,8153,422,835677,887Feb 12 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR